Business
Annexon Biosciences to Present Preclinical Data Supporting Complement Inhibitor Programs for the Treatment of Guillain-Barré Syndrome and Huntington’s Disease at AAN 2022
BRISBANE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new
About this update from Annexon, Inc.
[{"type":"text","content":"BRISBANE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders, today announced that the company will present preclinical data highlighting its approach of inhibiting C1q to address a number of complement-mediated diseases. The data are being presented in oral and poster sessions at the American Academy of Neurology (AAN) Annual meeting, being held in Seattle from April 2-7, 2022, and virtually from April 24-26, 2022. “Annexon was built on the hypothesis that inhibiting C1q and the early classical complement cascade right at the start could be translated into therapies that potentially provide more complete protection against a number of complement-mediated disorders,” said Ted Yednock, Ph.D., executive vice president and chief innovation officer of Annexon. “The data we are presenting at AAN support that hypothesis and the continued advancement of several of our clinical-stage programs, including those in Guillain-Barré Syndrome and Huntington’s disease. We look forward to sharing these data at the meeting and continuing to explore the potential of our pioneering approach to addressing complement-mediated diseases.” Oral PresentationsTitle: 001. Anti-C1q Therapy ANX005 Inhibits CSF Antibody-Driven Complement Activity Elevated in Early Stage Guillain-Barré SyndromeSession: S25: Autoimmune Neurology 2: Clinical Trials and TreatmentDate & Time: April 5, 2022, at 3:30 p.m. PT Title: 002. Effect of Combined Intravenous Immunoglobulin and Classical Complement Inhibitor ANX005 in Guillain-Barré SyndromeSession: S25: Autoimmune Neurology 2: Clinical Trials and TreatmentDate & Time: April 5, 2022, at 3:42 p.m. PT Title: 3372. Inhibition of C1q Reduces Nerve Damage as Measured by Neurofilament Light Chain in the HD R6/2 Mouse ModelSession: S36: Movement Disorders: Clinical and Pathologic Characterization of Neurodegenerative Movement DisordersDate & Time: April 7, 2022, at 1:36 p.m. PT Poster Presentation Title: 3302. Inhibiting C1q Improves Compound Muscle Action Potential and Reduces Neuronal Damage in the SOD1G93A Mouse ModelSession: P1: Neuromuscular Disease: Amyotrophic Lateral Sclerosis 1Date & Time: April 2, ...